期刊文献+

S-1联合DDP腹腔恒温循环热灌注治疗胃癌合并腹水的临床疗效观察 被引量:7

Clinical observation of therapeutic effects of S-1 combined with DDP circulatory thermochemotherapy of intraperitoneal perfusion for advanced gastric carcinoma with ascites
原文传递
导出
摘要 目的观察替吉奥(S-1)联合顺铂(DDP)腹腔循环热灌注化疗治疗胃癌合并腹水的临床疗效及不良反应。方法 134例患者随机分为试验组(循环热灌注组,n=67)和对照组(普通热灌注组,n=67)。S-1均按体表面积给药,服药2周,停药1周,DDP腹腔给药,d1 90 mg,d8 60 mg。试验组经恒温循环热灌注仪给药,对照组加入预热的41~43℃0.9%生理盐水100 ml直接腹腔注入。21 d为1周期,2周期后参照WHO标准评价客观疗效及不良反应。结果实际可评价134例,试验组腹水有效控制率为67.16%(45/67),对照组为47.76%(32/67),差异有统计学意义(P<0.05)。临床受益反应率为82.1%(55/67),对照组临床受益率为67.2%(45/67),差异有统计学意义(P<0.05)。两组不良反应主要为白细胞减少、贫血、恶心、呕吐等,组间无统计学差异(P>0.05)。结论与传统治疗方法相比,S-1联合DDP恒温循环热灌注治疗胃癌合并恶性腹水能取的更好的疗效且不增加毒副反应,值得进一步研究应用。 Objective To observe therapeutic effects and adverse effects of S-1 combined with DDP by circulatory thermochemotherapy of intraperitoneal perfusion for advanced gastric carcinoma with ascites. Methods 134 patients of advanced gastric carcinoma with malignant ascites were randomly divided into trial group(circulatory thermochemotherapy group, n=67) and control group(common thermochemotherapy group, n=67). All of patients in both groups were given with S-1 orally according to body surface area, twice daily for 2 weeks, drug withdrawl for 1 week. In trial group, 90 mg DDP was given on the first day and 60 mg DDP on the eighth day respectively by circulatory thermochemotherapy instrument. In control group, the same dosage of DDP was dissolved in 100 ml preheated 0.9% physiological saline(41-43℃) and injected into peritoneal cavity directly. Twenty one days makes a cycle, 2 cycles totally in both groups. The efficacy and adverse effects were evaluated according to the common toxicity criteria of WHO. Results 134 cases of patients could be given an objective evaluation of the efficacy and side effects. The response rate was 67.16%(45/67) in trial group and 47.76%(32/67) in control group (P〈0.05). The clinical benefit response rate was 82.1%(55/67) in trial group and 67.2%(45/67) in control group(P〈0.05). The adverse effects were no statistically significant difference between both groups(P〉0.05), mainly as leucopenia, anemia, nausea, and vomiting. Conclusion Comparing with the traditional treatment methods, cycle thermochemotherapy of intraperitoneal perfusion for advanced gastric carcinoma with malignant ascites can take better efficacy without increasing toxicity. It is worthy of studying further in clinic.
出处 《中华临床医师杂志(电子版)》 CAS 2013年第22期73-75,共3页 Chinese Journal of Clinicians(Electronic Edition)
关键词 替吉奥 顺铂 恒温循环热灌注 胃肿瘤 腹水 S-l Cisplatin Circulatory thermochemotherapy of intraperitoneal perfusion Stomachneoplasms Ascites
  • 相关文献

参考文献3

二级参考文献28

  • 1白娟,刘继彦.腹腔灌注治疗恶性腹水的现状与进展[J].华西医学,2007,22(2):428-429. 被引量:11
  • 2Munoz N,Franceschi S.Epidemiology of gastric cancer and perspectives for prevention.Salud Publica Mex 1997;39:318-330.
  • 3Kamangar F,Dores GM,Anderson WF.Patterns of cancer incidence,mortality,and prevalence across five continents:defining priorities to reduce cancer disparities in different geographic regions of the world.J Clin Oncol 2006;24:2137-2150.
  • 4Glimelius B,Ekstrom K,Hoffman K,Graf W,Sjodén PO,Haglund U,Svensson C,Enander LK,Linné T,Sellstrom H,Heuman R.Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.Ann Oncol 1997;8:163-168.
  • 5Webb A,Cunningham D,Scarffe JH,Harper P,Norman A,Joffe JK,Hughes M,Mansi J,Findlay M,Hill A,Oates J,Nicolson M,Hickish T,O'Brien M,Iveson T,Watson M,Underhill C,Wardley A,Meehan M.Randomized trial comparing epirubicin,cisplatin,and fluorouracil versus fluorouracil,doxorubicin,and methotrexate in advanced esophagogastric cancer.J Clin Oncol 1997;15:261-267.
  • 6Wagner AD,Grothe W,Haerting J,Kleber G,Grothey A,Fleig WE.Chemotherapy in advanced gastric cancer:a systematic review and meta-analysis based on aggregate data.J Clin Oncol 2006;24:2903-2909.
  • 7Van Cutsem E,Moiseyenko VM,Tjulandin S,Majlis A,Constenla M,Boni C,Rodrigues A,Fodor M,Chao Y,Voznyi E,Risse ML,Ajani JA.Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer:a report of the V325 Study Group.J Clin Oncol 2006;24:4991-4997.
  • 8Cunningham D,Starling N,Rao S,Iveson T,Nicolson M,Coxon F,Middleton G,Daniel F,Oates J,Norman AR.Capecitabine and oxaliplatin for advanced esophagogastric cancer.N Engl J Med 2008;358:36-46.
  • 9Kang Y,Kang WK,Shin DB,Chen J,Xiong J,Wang J,Lichinitser M,Salas MP,Suarez T,Santamaria J.Randomized phase III trial of capecitabine/cisplatin (XP) vs.continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC):efficacy and safety results.Proceedings of the 42nd Annual Meeting of American Society of Clinical Oncology;2006 June 1-5;Chicago,USA.Alexandria:American Society of Clinical Oncology,2006:18s.
  • 10Koizumi W,Narahara H,Hara T,Takagane A,Akiya T,Takagi M,Miyashita K,Nishizaki T,Kobayashi O,Takiyama W,Toh Y,Nagaie T,Takagi S,Yamamura Y,Yanaoka K,Orita H,Takeuchi M.S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial):a phase III trial.Lancet Oncol 2008;9:215-221.

共引文献73

同被引文献56

  • 1刘莉,姚军霞,丁乾,黄士昂.非霍奇金淋巴瘤患者外周血CD4^+CD25^(high)调节性T细胞研究[J].中国实验血液学杂志,2006,14(1):119-122. 被引量:30
  • 2Jemal A, Bray F, Center MM, et al. Global cancer statistics [J]. CA Cancer J Clin, 2011,61 (2) : 69 - 90.
  • 3Zhao C, Dai C, Chen X. Whole -body hyperthermia combined with hyper- thermic intraperitoneal chemotherapy for the treatment of stage IV ad- vanced gastric cancer [J]. Int J Hyperthermia, 2012,28 (8) : 735 - 741.
  • 4Seshadri RA,Glehen O.The Role of Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer[J].Indian J Surg Oncol,2016,7(2):198-207.
  • 5Bhatt A,Glehen O.The role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy(HIPEC)in Ovarian Cancer:A Review[J].Indian J Surg Oncol,2016,7(2):188-197.
  • 6Petrillo M,Anchora LP,Scambia G,et al.Cytoreductive Surgery Plus Platinum-Based Hyperthermic Intraperitoneal Chemotherapy in Epithelial Ovarian Cancer:A Promising Integrated Approach to Improve Locoregional Control.[J].Oncologist,2016,21(5):532-534.
  • 7Jian-Hua Sun,Zhong-He Ji,Yang Yu,et al.Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy to Treat Advanced/Recurrent Epithelial Ovarian Cancer:Results from a Retrospective Study on Prospectively Established Database[J].Translational Oncology,2016,9(2):130-138.
  • 8Feingold PL,Kwong ML,Sabesan A,et al.Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for gastric cancer and other less common disease histologies:is it time?[J].J Gastrointest Oncol,2016,7(1):87-98.
  • 9Esquivel J.Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer:survival outcomes and patient selection[J].J Gastrointest Oncol,2016,7(1):72-78.
  • 10Sluiter NR,de Cuba EM,Kwakman R,et al.Versican and vascular endothelial growth factor expression levels in peritoneal metastases from colorectal cancer are associated with survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy[J].Clin Exp Metastasis,2016,33(4):297-307.

引证文献7

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部